Data in Nine Difficult-to-Treat Cancers from Merck’s KEYTRUDA® (pembrolizumab) Development Program to be Presented at European Cancer Congress 2015, Including Data in Four New Cancer Types: ...
Dateline City:
KENILWORTH, N.J.
...Nasopharyngeal Carcinoma, Anal Cancer, Merkel Cell Carcinoma and Biliary Tract Cancer
Data to Include First-Time Findings on the Potential Importance of PD-L2 Expression in Predicting Patient Responsiveness to Anti-PD-1 Therapy
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
announced today that new data investigating the anti-tumor activity of
KEYTRUDA® (pembrolizumab) across a broad range of advanced
cancers will be presented at this year’s European Cancer Congress (ECC)
in Vienna, Austria, Sept. 25-29. In total, 15 KEYTRUDA-related abstracts
across nine difficult-to-treat cancers will be presented at this year’s
ECC – including four late-breaking oral presentations.
Language:
English
Contact:
MerckMedia:Pamela Eisele, 267-305-3558orAn Phan, 908-255-6325orInvestors:Teri Loxam, 908-740-1986orJustin Holko, 908-740-1879
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Product News - Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Research and Development News Corporate News Latest News Source Type: news
More News: Anal Cancer | Cancer | Cancer & Oncology | Carcinoma | Drugs & Pharmacology | Merck | Merkel Cell Carcinoma | Nasopharyngeal Cancer | Oral Cancer | Politics